Baxter International Inc (BAX)
Health Care · Health Care Equipment · US stock · S&P 500 component
$25.28
▼ -0.48 (1.86%)
Day's range
$25.13 – $25.99
52-week range
$15.72 – $29.99
About Baxter International Inc
Hospitals and other care settings use the medical products made by Baxter International. Its range includes intravenous solutions and infusion pumps, injectable medicines, surgical products, and hospital beds, patient monitoring and other connected-care technology. Customers are hospitals, health systems, pharmacies and clinics around the world. The company reports its activity in groups covering medical products and therapies, healthcare systems and technologies, and pharmaceuticals.
Revenue of $11.5 billion over the last twelve months comes from recurring medical consumables and injectable products, together with equipment and related services. Sales have grown at 3.8% a year across the last three years. The operating margin is -2.4%, the business earns -4% on the capital invested in it, and net debt is -1.9 times EBITDA. The dividend yield is 0.2%. On the site's X-Ray Score it receives 29 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $15.72 – $29.99Volume 4,406,400Daily, split-adjusted
Vitals
Market cap$13.1B
52-week range$15.72 – $29.99
Volume (last day)4,406,400
P/E (TTM)–
EBIT / EV yield-2.3%
Free-cash-flow yield–
Dividend yield0.2%
Revenue (TTM)$11.5B
Net income (TTM)−$1.1B
Operating margin-2.4%
Return on capital-4.4%
Debt incl. leases$844M
Cash & securities$2.2B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
Not rated
Loss-making or insufficient history: no DCF/EPV
What this means
Read the lenses below
A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
26/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield-2.3%
Growth
Weak
38/100
Growing slower than most of its sector.
See the numbers →
Revenue growth (3y)3.8%
Growth consistency100%
Profitability
Weak
23/100
Earns lower returns on its capital than most peers.
See the numbers →
Return on invested capital-4.4%
Operating margin-2.4%
Gross profitability17.4%
Financial health
Weak
46/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score5 / 9
Net debt / EBITDA-1.9×
Interest cover-0.9×
Dividends
Weak
3/100
Dividend is modest or less certain than peers.
See the numbers →
Dividend yield0.2%
Dividend growth-15.3%
Quarterly results: last 6 quarters
+5.4%
Mar '25
+4.3%
Jun '25
+5.0%
Sep '25
+8.0%
Dec '25
+2.9%
Mar '26
+5.3%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $3.0B, diluted EPS $0.24.
Compare with peers
RMD Resmed Inc73 DXCM Dexcom Inc71 PODD Insulet Corp69 IDXX Idexx Laboratories Inc67Other Health Care Equipment companies by X-Ray Score.
Fundamentals checklist
● 4 Good · ● 2 Average · ● 7 BadCash quality
Earnings backed by cashGood
Risk models
Altman Z''Average
Piotroski F-ScoreBad
Growth
Free-cash-flow growth (3y)Bad
Revenue growth (3y)Average
Growth consistencyGood
Balance sheet
Current ratioGood
Net debt / EBITDAGood
Interest coverBad
Valuation
EBIT / EV yieldBad
Profitability
Return on invested capitalBad
Operating marginBad
Gross profitabilityBad
Each check is graded against the company's sector, not a fixed number. Checklist score 38/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $12.1B | $10.1B | $10.4B | $10.6B | $11.2B |
| Operating income | $1.4B | −$2.8B | $707M | $14M | −$308M |
| Net income | $1.3B | −$2.4B | $2.7B | −$649M | −$957M |
| Operating cash flow | $2.2B | $1.2B | $1.7B | $1.0B | $845M |
| Operating margin | 11.1% | -28.3% | 6.8% | 0.1% | -2.7% |
| Free cash flow | $1.5B | $834M | $1.3B | $573M | $332M |
| Diluted EPS | $2.53 | $-4.83 | $5.23 | $-1.27 | $-1.87 |
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
12 bullish · 3 neutral · 1 bearish
Weekly
Strongly bullish
9 bullish · 1 neutral · 2 bearish
Monthly
Bullish
5 bullish · 1 neutral · 2 bearish
Moving averages (daily)
| SMA 10 | 24.63 | Bullish |
| EMA 10 | 24.73 | Bullish |
| SMA 20 | 24.07 | Bullish |
| EMA 20 | 24.46 | Bullish |
| SMA 50 | 25.00 | Bullish |
| EMA 50 | 24.29 | Bullish |
| SMA 100 | 23.46 | Bullish |
| EMA 100 | 23.42 | Bullish |
| SMA 200 | 21.09 | Bullish |
| EMA 200 | 22.69 | Bullish |
Oscillators (daily)
| RSI (14) | 59.47 | Neutral |
| MACD (12, 26) | 0.20 | Bullish |
| Momentum (12) | 5.33 | Bullish |
| Stochastic %K (14) | 75.00 | Neutral |
| Williams %R (14) | -25.00 | Neutral |
| CCI (20) | 167.4 | Bearish |
Pivot points (classic, last session)
S3 24.08 | S2 24.61 | S1 24.94 | Pivot 25.47 | R1 25.80 | R2 26.33 | R3 26.66 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Dividends
Paid, last 12 months
0.04 USD
Yield on today's price
0.16%
Frequency
Quarterly
Next ex-dividend date
Not announced
| Ex-dividend date | Amount per share |
|---|---|
| 28 Aug 2026 | 0.0100 |
| 29 May 2026 | 0.0100 |
| 27 Feb 2026 | 0.0100 |
| 28 Nov 2025 | 0.0100 |
| 29 Aug 2025 | 0.1700 |
| 30 May 2025 | 0.1700 |
| 28 Feb 2025 | 0.1700 |
| 29 Nov 2024 | 0.1700 |
| 30 Aug 2024 | 0.2900 |
| 31 May 2024 | 0.2900 |
| 29 Feb 2024 | 0.2900 |
| 30 Nov 2023 | 0.2900 |
Ex-dividend dates and amounts from EODHD. Shown as declared, before tax.
BAX SEC filings
19 Aug 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
18 Aug 2026
8-KSEC EDGAR
Entered a material agreement; Other events
4 Aug 2026
8-KSEC EDGAR
Other events
4 Aug 2026
8-KSEC EDGAR
Director or officer change
30 Jul 2026
10-QSEC EDGAR
Quarterly report
30 Jul 2026
8-KSEC EDGAR
Results of operations; Other events
14 Jul 2026
8-KSEC EDGAR
Regulation FD disclosure
8 May 2026
8-KSEC EDGAR
Director or officer change; Shareholder vote results
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.